Cell Therapeutics files Zevalin for first-line consolidation use in NHL
This article was originally published in Scrip
Executive Summary
Cell Therapeuticshas filed a supplemental BLA with the US FDAfor the use of its radioimmunotherapy drug Zevalin ([90Y]-ibritumomab tiuxetan) as a consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma (NHL). It has requested priority review, which, if granted, would result in a six-month review period.